A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms DREAM
- Sponsors DAE HWA Pharmaceutical
- 09 Feb 2018 Primary endpoint (Progression-free survival (PFS)) has been met as per the results published in the Annals of Oncology.
- 09 Feb 2018 Results published in the Annals of Oncology
- 10 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.